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Abstract   This is a review of the hip arthroplasty era. We con-
centrate on new metal bearings, surface replacements, and the 
lessons not learned, and we highlight recent reports on malig-
nancies and joint implants. A low incidence of blood malignan-
cies has been found in bone marrow taken at prosthetic surgery. 
The incidence is increased after replacement with knee implants 
that release very low systemic levels of metal ions. A carcinogenic 
effect of the high levels of metal ions released by large metal-on-
metal implants cannot be excluded. Ongoing Swedish implant 
registry studies going back to 1975 can serve as a basis for evalu-
ation of this risk.

Historical considerations
After more than 3 decades of limited success with hemiarthro-
plasty, the total hip arthroplasty (THA) era started in the 1950s 
in Europe. In 1953, the McKee 32-mm metal head articulating 
against a metal cup (MOM) made of cobalt-chromium was 
introduced (McKee and Watson-Farrar 1966). The success 
with low-friction arthroplasty (LFA) (Charnley 1961) was 
a dramatic leap forward, at the start only hampered by deep 
infections in up to 10% of the cases. At the beginning of the 
1970s, strict aseptic and antiseptic routines combined with 
systemic and local antibiotic prophylaxis reduced the risk of 
infection to less than 1% (Lidgren 2001, Jämsen et al. 2010). 
The initial outcome with the cemented MOM THA was 
also promising, but early on it resulted in 2 main failure pat-
terns (Benson et al. 1975). Loosening and migration of the 
acetabular cup occurred due to high friction and impact forces. 
Secondly, local inflammation around the implant with black-
tinted tissue was observed in early revisions for pain, and it 
was believed to be caused by metal wear particles (Evans et 
al. 1974). Improved production of the McKee with matched 
components led to jamming, and increased the failure rate 
even more. Coleman et al. (1973) reported a 15-fold increase 
in Cr in urine and an 11-fold increased level of Co in whole 
blood (Coleman et al. 1973). In addition, Benson et al. (1975) 
showed a high incidence of metal sensitivity in MOM McKee-
Farrar THA compared to metal-to-plastic THA. 
In a short-term follow-up of MOM McKee-Farrar THA, 
revision had been done in 15% of cases at 4 years (Baldursson 
1980). Single long-term studies have, however, also reported 
prosthetic survival in up to 75% of cases at 20 years (Brown 
et al. 2002). At the end of 1970, the McKee-Farrar MOM con-
cept was abandoned in favor of the LFA concept, which has 
had a well-documented excellent long-term outcome (Cal-
laghan et al. 2000, Learmonth et al. 2007).
Surface replacement
A partly new idea, the surface replacement (SR), was intro-
duced in 1974 by Wagner in Germany (Wagner 1978). A large 
(44 mm or more) 3-mm-thick stainless steel cup was placed on 
the preserved femoral head and a thin polyethylene cup (4–6 
mm) was inserted in the acetabulum. As early as the 1930s, 
the same concept—but as a mold hemiarthroplasty—had been 
introduced, first made of glass but later made of stainless 
steel (Smith-Petersen 1948). The joint-preserving SR method 
quickly became popular, especially in active young patients, 
reducing the risk of dislocation. But soon afterwards, new 
complications were reported, i.e. cervical neck fractures due 
to several factors such as femoral notching and loosening of 
the femoral cup secondary to bone necrosis (enhanced by par-
ticles and circulatory disturbances). In addition, the thin poly-
ethylene acetabular cup was deformed and it added to a high 
early failure rate (Mogensen et al. 1982). A long-term study 
of the original Wagner SR showed that after 22 years, only 
11 of 270 patients still had this prosthesis left in situ (Costi et 
al. 2010). In 16% of the revisions, loosening was only found 
on the femoral side. Until the start of the new millennium, the 
SR method had a strong foothold in the USA (Amstutz et al. 
1998).
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Metal on metal 
It was expected that when the MOM THA concept was revis-
ited by Weber in Switzerland in the 1980s (Weber 1996, Ran-
delli et al. 2012)—and followed in the 1990s by the Birming-
ham MOM SR in the UK (Carrothers et al. 2010)—that some 
of the earlier observations and experience of outcome during 
the previous 70 years had been taken into consideration. The 
new cobalt-chromium MOM joint bearings were tested tribo-
logically by wear-simulator testing and were claimed to over-
come the high friction and wear seen earlier with the McKee-
Farrar MOM THA. The risk of femoral neck fracture and loos-
ening were expected to diminish with surgical training using a 
more gentle technique and better instrumentation.
The initial early success reported by Daniel et al. already 
in 2004 resulted in a number of “generic” MOM SR pros-
theses being quickly released by competing companies; these 
were based on a predicative 510 K process, starting from the 
BHR approval in May 2006 (http://www.fda.gov/downloads/
MedicalDevices/DeviceRegulationandGuidance/GuidanceD-
ocuments/ucm080189.pdf). At the same time, several MOM 
THAs made of cobalt-chromium were reintroduced with the 
same claim that the new high-precision production methods 
should give less friction than the LFA. In the USA in 2009, 
approximately one third of the hip joint procedures were large 
MOM articulations (Bozic et al. 2010). 
Based on the data available today, it is possible to con-
clude that, except for there being less dislocation with a larger 
head, none of the claims have come true. For some of the new 
implants with minimal clearance between the larger metal 
components, this has resulted (as before) in jamming from 
local polar edge contact, with wear and increased blood metal 
ion levels if perfect positioning is not achieved (De Haan et 
al. 2008, Langton et al. 2008, Hart et al. 2009). There have 
been no clinical studies verifying the importance of lubrica-
tion and optimal clearance between the bearing surfaces for 
new implant designs. 
There is still an increased risk of early revision, of 1.5–3%, 
for femoral neck fractures with MOM SR (Steffen et al. 2009). 
Isolated femoral complications could be expected to increase 
further with time from age-related fragility, accelerated stress 
shielding, and particle reaction—especially in women with a 
small neck-to-head ratio.
Metal wear and particle release is a major issue with the 
new larger bearings, despite the improved tribology verified 
on the bench. Shedding of large amounts of particles may 
occur, leading to painful local inflammation and reoperation 
(Smith et al. 2012). About one trillion small nanoparticles 
are released in a year in a MOM bearing, which is 14,000 
times more particles than with an LFA articulation (Daniel 
et al. 2012). Recent studies have shown that in patients with 
well-functioning implants, the average serum levels of Co and 
Cr are 1–2 μg/L. Levels of up to 387 μg/L for Co and 179 
μg/L for Cr have, however, been found. Very high levels in the 
fluid surrounding a MOM THA have been measured: up to 
400 mg/L of Cr and up to 22 mg/L of Co (Sampson and Hart 
2012, Srinivasan et al. 2011). In a MOM THA with a modular 
morse-taper head-neck junction, with metal-on-metal contacts 
and possible corrosion, the particle release may be even higher 
(Meyskens and Yang 2011).
Large aggregations of lymphocytes, so-called pseudotu-
mors, in asymptomatic patients studied with ultrasound have 
been reported in as many as one third of them operated with 
a MOM THA (Williams et al. 2011, Wynn-Jones et al. 2011). 
Technical aspects of performing MRI after hip arthroplasty 
were reviewed recently (Hayter et al. 2012). In a recent reg-
istry study from the UK, a clinical failure rate up to 6% in 
females was found at 5 years for MOM THA (Smith et al. 
2012b). The authors reported less revisions with smaller 
MOM THA articulations, but the rates were still significantly 
higher than for the metal-on-plastic LFA. 
There are significant differences between metal-on-metal 
concepts, and it might be unfair to lump them together. Excel-
lent results have been reported with the Pinnacle MOM pros-
thesis, for example, with 98% survival at 7 years (Kindsfater 
et al. 2012).
That the ASR MOM SR with a less hemispherical cup 
design is a clear outlier was first reported in Australia (De 
Steiger et al. 2011), but during the last 2 years several other 
MOM hip prostheses with large joint bearings have been with-
drawn. There has been company-initiated post-marketing sur-
veillance, with patients being informed, and also largely in 
cooperation with the orthopedic profession. Very recently, the 
problems have also been taken up by a few regulatory bodies. 
The lack of international coordination and the need for an 
independent alert system has been emphasized in 3 succes-
sive articles (Langton et al. 2008, Cohen 2011, Heneghan et 
al. 2012). 
Malignancy and metal ion release
A recent concern has been whether the large amount of 
cobalt and chromium nanoparticles released could cause 
cancer (http://www.mhra.gov.uk/NewsCentre/Pressreleases/
CON143784).
The most relevant systems and organs that might be affected 
in the medium term (the first 10–20 years) are the hematopoi-
etic system, the urogenital system, and the skin. In the long 
term (20–40 years), the solid organs might be affected (Little 
2009).
By cross-checking of hospital data with national cancer 
databases, it would be possible to obtain information on 
increased risk. This has been done with some consistent 
results on hematopoietic tumors, but with less convincing 
data on other tumors except prostate cancer and melanoma 
(Lewold et al. 1996, Lidgren 2008, Wagner et al. 2011). Often, 
rheumatoid arthritis (with a higher risk of tumor development) 
is not differentiated from OA; with information taken from 
hospital systems, this raises some concern about the reliability 
of the data from the studies already published. A recent short-
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term study (Smith et al. 2012a) using the NHS joint register 
and hospital data from England and Wales found no overall 
increase in solid and hematopoetic cancer, and also no differ-
ences comparing LFA with MOM SR and MOM THA. The 
median observation time was only 2.8 years, and there was no 
differentiation between RA and OA.
The specific increase in hematopoetic tumors has recently 
been verified in a long-term follow-up in a joint replacement 
registry for patients who received knee prostheses for RA 
but—never before reported—for OA (Wagner et al. 2011). The 
release of metal in a metal-to-polyethylene knee joint (TKA) 
could be expected to be higher than for an LFA because of a 
bearing contact area that is 10 times greater. The wear patterns 
in the knee joint are well described, and result in larger plastic 
particles than those produced in prosthetic hips (Blunn et al. 
1992, 1997, Goodman and Lidgren 1992). Co-Cr levels have 
been reported to be comparable to those with well-functioning 
MOM THA with a small head, and to be only slightly elevated 
than those for LFA (Luetzner et al. 2007, Garrett et al. 2010). 
Several studies have, however, shown higher levels in hinged 
or semiconstrained TKA (Liu et al. 1998) and loose TKA 
(Sunderman et al. 1989, Liu et al. 1998).
Several authors have reported an increase in melanoma 
after joint prosthetic surgery (Nyren et al. 1995, Onega et al. 
2006, Visuri et al. 2006, Wagner et al. 2011). It is reasonable 
to suspect that this is caused by higher long-term exposure to 
chromium released from the implant. Hexavalent chromium 
especially has a profound effect on melanocytes at low levels 
(Meyskens and Yang 2011). In future, the use of X-ray syn-
chronization radiation methods may allow measurement of 
chromium in single cells (Bohic et al. 2008). This should be 
studied in more detail in MOM joints that shed a large amount 
of smaller particles. It might be time to start discussing 
whether actively giving advice on sun protection to patients 
with large MOM bearings and high serum levels of chromium 
is indicated. Development of novel UV-activated chromium-
protective chelators was suggested for melanoma prevention 
not related to joint implants before the MOM era (Yiakouvaki 
et al. 2006).
Regarding the urogential tract, our earlier findings of a 
slight increase in prostatic cancer (Wagner et al. 2011) have 
recently come into focus after unexpected findings of epithe-
lial precancer in the bladders of MOM THA patients; this was 
reported at the British Hip Society meeting in 2012 (Maclean 
et al., unpublished observations). An additional study with 
longer follow-up, reported at the same BHS meeting, found, 
however, that there was no increase in urogenital malignancies 
(Kumar et al., unpublished observations). Thus, these findings 
must be verified statistically and confirmed epidemiologically 
before any association between an implant and urogenital 
malignancy can be considered. 
Joint disease and tumor
It is well known that inflammation influences tumor develop-
ment. This is evident in a number of inflammatory musculosk-
eletal conditions such as RA, Sjögren’s syndrome, and SLE. 
An increased risk has been seen for lymphatic tumors espe-
cially (Solomon et al. 2012). Interestingly, anti-inflammatory 
steroid treatment in RA reduces the risk of developing lym-
phoma (Hellgren et al. 2010). It has been postulated that it is 
the severity of inflammation and duration of the rheumatoid 
arthritis that contributes to the increased risk of lymphoma 
(Askling et al. 2009). The risk of hematological cancer is 
higher in younger RA patients (Chen et al. 2011).
There is also evidence that patients with seronegative arthri-
tis have an increased risk of developing myelodysplastic 
malignancies (MDS) (Chandran et al. 1996). In smaller patient 
series, blood malignancies (i.e leukemia and lymphoma) have 
been diagnosed in patients who have developed osteonecrosis 
(Kozuch et al. 2000). The immunological and thrombogenic 
malignant cascade that results in impaired circulation and 
therefore osteonecrosis is only partially understood.
The question is therefore whether osteoarthritis could also 
initiate and drive hematopoietic malignancies irrespective of 
the implant intervention. At replacement surgery, in advanced 
cases we often find inflammation and large subchondral cysts 
filled with fluid and hypertrophic synovial tissue. 
As part of bone bank routines, between 1994 and 2005 a 
Dutch group investigated 852 donor femoral heads for malig-
nancies, using histology. They found unexpectedly that 14 
(1.6%) had malignant cells indicative of low-grade B cell lym-
phoma (Zwitser et al. 2009). At a follow-up after an average of 
7 (1–12) years, 2 of the donors had developed active disease 
and 3 more were being followed up by an oncologist because 
of suspected disease. None of the recipients who accidently 
received a low-grade lymphoma bone transplant had devel-
oped an MDS malignancy. 
In a recent large study of 6,161 osteoarthritic femoral heads 
donated for transplantation in Perth, Australia, 19 patients had 
an unexpected neoplasm in the femoral head, 9 of which had 
systemic disease on further investigation; all of them were 
hematologic malignancies. Thus, 1 verified malignancy in 
770 femoral heads was found. This is much lower than in the 
Dutch study, but in addition 45 femoral heads had a nodular 
lymphocyte infiltration and plasmocytosis was found in 10 
femoral heads (Mackie et al. 2011). This is similar to the find-
ings by Palmer et al. (1999), with 3 malignancies in 1,146 
femoral heads. 
It was suggested in the paper my Mackie et al. (2011) that 
routine histology of the removed bone should be carried out 
in all joint replacements, and that this would be a cost-effec-
tive routine for screening for blood malignancies. The ethical 
implications of how to handle the finding of malignancy in a 
donor have not been discussed in the literature.
Lymphoid aggregation is accidently found in bone marrow 
at post-mortem studies, and increases with age. The distinc-
tion between benign reactive aggregates and well-differenti-
ated lymphoma may be difficult, and it is also unclear whether 
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and how a tumor transition in OA takes place, probably driven 
by inflammation. 
The findings in the Australian, Dutch, and UK studies were 
similar regarding lymphoma, myelodysplasia, and myelopro-
liferative lymphoid aggregations. It is important that one third 
of the indolent local blood malignancies found in the Dutch 
study over an observation period of less than 10 years devel-
oped an overt systemic blood disease.
Does a joint implant drive malignancy in blood?
One remaining concern is whether a specific joint implant 
will accelerate and/or start tumor development over a longer 
period of time.
As mentioned, it has been clearly shown that it is possible 
to have an indolent local malignancy in the bone marrow 
adjacent to an osteoarthritic joint. In cases of resection of the 
joint, i.e. on total joint replacement and if the tumor is only 
located adjacent to the joint, this might prevent tumor devel-
opment. Whether or not this will have any influence on the 
MOM SR concept is unclear, and it is unlikely considering the 
generalized nature of MDS and lymphoma. All the published 
long-term studies on small MOM bearings and hematological 
malignancies have been on total joint replacements where the 
proximal and distal parts of the joint have been resected, i.e. 
McKee-Farrar THA. Due to the vast amount of large MOM 
bearings inserted in the USA and the UK, this should be ana-
lyzed continuously and needs to be followed in the long term. 
Pooling and aggregation of the available ongoing MOM reg-
istry data from several countries is possible, but complicated 
because of data-protection laws. However, cross-checking of 
joint registries with the national cancer registries is warranted.
As an extension of our and others’ earlier published stud-
ies (Lewold et al. 1996, Lidgren 2008, Mackie et al. 2011, 
Wagner et al. 2011), we compared the incidence of hema-
tological malignancies taken from the national cancer data-
base in Sweden, bone biopsy tumor findings from the large 
Australian Hip OA cohort, and data from OA patients in the 
prospective national knee prosthetic register cohort in Sweden 
(going back to 1975 and covering all clinics). The aim was 
therefore to determine whether there has been—in addition to 
the baseline level of malignancies seen in bone marrow at pri-
mary prosthetic replacement—a long-term increase in blood 
malignancies related to joint implants releasing low levels of 
metal particles. This could give some indication of the follow-
up necessary for MOM bearings releasing several orders of 
magnitude higher levels of metal ions. 
Assuming that the disease duration of hematological malig-
nancies was equal in the Australian and Swedish knee cohorts, 
an approximate annual incidence of 31/105 could be calcu-
lated using the prevalence of indolent blood malignancies 
in femoral heads taken from the large Australian study (De 
Steiger et al. 2011). This is almost the same incidence as was 
observed using data from the Swedish study (Wagner et al. 
2011) in the 10 years prior to knee replacement: 34/105. After 
surgery, the Swedish incidence of blood malignancies was 
137/105 (unpublished data). The corresponding incidence in 
the general population of Sweden, had it had the same sex-, 
age-, and calendar-year distribution, would have been 81/105 
before the operation and 122/105 afterwards. Part of this 
increase in incidence may have been due to changes in the 
cohort’s distribution of age, sex, and calendar year. 
Furthermore, the low preoperative incidence level may have 
been affected by the fact that the preoperation cohort was a 
selected population, as it is likely that it included healthier 
individuals than in the general population, with respect to 
hematological malignancies. Consequently, the most severe 
cases were automatically excluded. In addition, patients with 
multiple diseases and in poor condition because of comorbidi-
ties may have been prevented from having surgery, thereby 
excluding them from the preoperative knee cohort. 
However, irrespective of whether the increase was caused 
by other confounding factors such as frequent radiation expo-
sure and virus infection, or indeed metal exposure, these data 
can be seen as a baseline reference for an extended follow-up 
of large MOM bearings.
The blood malignancies diagnosed in the bone marrow at 
prosthetic replacement could not fully explain the low but 
clear increase found after long-term knee replacement. We 
therefore propose that the pre-existing condition of lymphoid 
aggregates in OA may be further activated by metal ions after 
implantation. Depending on the stage of the condition, the 
combination of OA pathology in bone marrow and the reac-
tion to metal ions after implantation can contribute to the 
development of the blood malignancies. 
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